Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GLP-2 on Gallbladder Motility in Healthy Subjects
NCT03682172Phase 1Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glucagon-like peptide-2 (3 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Gallbladder ejection fraction. Started May 2018; status: completed.
02
Drugs
glucagon-like peptide-2
Beyond the preview
Go deeper on NCT03682172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682172.